Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of metastatic or surgically unresectable transitional cell carcinoma of the urothelium involving the bladder,urethra,ureter or renal pelvis~* Measurable disease by CT or MRI~* Progression or recurrence after treatment~* i) With at least 1 platinum-containing chemotherapy regimen for metastatic or surgically unresectable locally advanced urothelial cancer, or~* ii) Within 12 months of peri-operative (neo-adjuvant or adjuvant) treatment with a platinum agent in the setting of cystectomy for localized muscle-invasive urothelial cancer~* Subject that have received more than 2 prior lines of chemotherapy must not have liver metastases~* Tumor tissues (archived or new biopsy) must be provided for biomarker analysis~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1~Exclusion Criteria:~* Subjects with active cancer that has spread to the central nervous system~* Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured~* Subject with active, known or suspected autoimmune disease~* Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 day of study drug administration~* Prior treatment with an anti-PD-1,anti-PD-L1,anti-PD-L2,anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, anti-CD137 or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways~Exclusion laboratory criteria:~* Positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection~* Known history of testing positive for human Immunodeficiency virus (HIV) or known acquired Immunodeficiency syndrome (AIDS)~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).